November 25, 2009 (FinancialWire) — Affymax, Inc. (NASDAQ: AFFY) has closed an underwritten public offering of 4,726,027 shares of its common stock, which includes the full exercise of the underwriter’s overallotment option of 616,438 shares. Cowen and Co. (NASDAQ: COWN) and Lazard Capital Markets (NYSE: LAZ) were joint bookrunners.

The net proceeds to the company after deducting underwriting discounts and commissions and estimated offering expenses are approximately $80.0 million.

Affymax is a biopharmaceutical company focused on developing novel drugs to improve the treatment of serious and often life-threatening conditions.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports, filings and conference call webcasts for companies mentioned in the news are available via Investrend Syndications (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.